))
#2 - A biomaterial-based vaccine
Manage episode 429175496 series 3586580
Accelerating Cancer Immunotherapy Research (ACIR)에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Accelerating Cancer Immunotherapy Research (ACIR) 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/
Thanks for listening! Let’s stay in touch:
- Tweet us at @ImmunoTalks
- Share our episodes on LinkedIN and Instagram
- Email us at contact@acir.org
챕터
1. #2 - A biomaterial-based vaccine (00:00:00)
2. Background about the study (00:00:29)
3. GUEST: Alex Najibi (00:05:30)
3 에피소드
공유
